The overall survival and disease/progression-free survival rates for HCC patients with NEK2, NDC80 and CEP250 genetic alterations were significantly lower than those without the alterations of the three gene (p = 0.0426 and 0.0341, respectively, Fig. 7). The gene discussed is NEK2; the disease is hepatocellular carcinoma.